Table 4.
HPV Risk Groupa | CP-Diagnosed CIN2 | |||||||
---|---|---|---|---|---|---|---|---|
p16 IHC Negative | p16 IHC Positive | |||||||
<HSIL Cytology | HSIL+ Cytology | <HSIL Cytology | HSIL+ Cytology | |||||
N | % Col | N | % Col | N | % Col | N | % Col | |
HPV16 | 61 | 20.4 | 18 | 22.5 | 284 | 36.7 | 88 | 42.7 |
HPV18/45 | 16 | 5.4 | 9 | 11.3 | 54 | 7.0 | 17 | 8.3 |
Other high riskb | 127 | 42.5 | 28 | 35.0 | 360 | 46.5 | 87 | 42.2 |
Intermediate riskc | 21 | 7.0 | 5 | 6.3 | 46 | 5.9 | 8 | 3.9 |
Low riskd | 15 | 5.0 | 1 | 1.3 | 6 | 0.8 | 0 | 0.0 |
HPV negative | 59 | 19.7 | 19 | 23.8 | 24 | 3.1 | 6 | 2.9 |
Ptrend (versus CIN3e) | <.001 | <.001 | <.001 | .012 |
One hundred fifty-three cases were missing antecedent cytology results. “% Col” is the column percentage, that is, the number in cell divided by the total column number.
Defined hierarchically according to cancer risk.
HPV31, 33, 35, 39, 51, 52, 56, 58, 59, and 68.
HPV26, 53, 66, 67, 70, 73, and 82.
HPV6, 11, 40, 42, 54, 55, 61, 62, 64, 69, 71, 72, 81, 82v, 83, 84, and 89.
Compared to data combining p16 IHC–negative and p16 IHC–positive CIN3 from Table 1.